002675 东诚药业
交易中 07-22 13:44:18
资讯
新帖
简况
东诚药业：177Lu-LNC1011为前列腺癌治疗核素药物
证券之星 · 07-07
东诚药业：177Lu-LNC1011为前列腺癌治疗核素药物
东诚药业（002675）披露回购公司股份进展情况公告，7月1日股价上涨1.83%
证券之星 · 07-01
东诚药业（002675）披露回购公司股份进展情况公告，7月1日股价上涨1.83%
东诚药业：18F-LNC1001思睿肽注射液目前正在审核中
证券之星 · 07-01
东诚药业：18F-LNC1001思睿肽注射液目前正在审核中
东诚药业（002675）披露为合营公司提供8000万元担保进展，6月30日股价下跌1.49%
证券之星 · 06-30
东诚药业（002675）披露为合营公司提供8000万元担保进展，6月30日股价下跌1.49%
股市必读：东诚药业（002675）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：东诚药业（002675）6月18日董秘有最新回复
东诚药业最新公告：子公司蓝纳成重新递交H股上市申请
证券之星 · 06-15
东诚药业最新公告：子公司蓝纳成重新递交H股上市申请
东诚药业(002675.SZ)：吉林长春核药生产中心投入运营
智通财经 · 06-15
东诚药业(002675.SZ)：吉林长春核药生产中心投入运营
蓝纳成冲刺港股：年亏1.5亿 东诚药业是大股东
雷递网 · 06-14
蓝纳成冲刺港股：年亏1.5亿 东诚药业是大股东
东诚药业：氟[18F]思睿肽注射液不符合医保目录预申报条件
证券之星 · 06-09
东诚药业：氟[18F]思睿肽注射液不符合医保目录预申报条件
东诚药业：齐康原的回旋加速器项目尚未正式投产
证券之星 · 06-03
东诚药业：齐康原的回旋加速器项目尚未正式投产
东诚药业：公司目前持有四川中硼联康医疗科技集团有限公司10.3949%的股份
证券之星 · 06-03
东诚药业：公司目前持有四川中硼联康医疗科技集团有限公司10.3949%的股份
东诚药业（002675）披露为全资子公司提供3亿元担保公告，6月2日股价下跌0.39%
证券之星 · 06-02
东诚药业（002675）披露为全资子公司提供3亿元担保公告，6月2日股价下跌0.39%
东诚药业：东诚安迪科与诺华开展核药供应链相关的业务合作
证券之星 · 06-02
东诚药业：东诚安迪科与诺华开展核药供应链相关的业务合作
东诚药业（002675）披露2026年第一次临时股东会决议公告，5月28日股价下跌0.32%
证券之星 · 05-28
东诚药业（002675）披露2026年第一次临时股东会决议公告，5月28日股价下跌0.32%
东诚药业：蓝纳成证监会备案正在审理中
证券之星 · 05-28
东诚药业：蓝纳成证监会备案正在审理中
东诚药业：云克药业的钇90核素已开展定制化生产
证券之星 · 05-21
东诚药业：云克药业的钇90核素已开展定制化生产
东诚药业：氟[18F]思睿肽注射液已获上市申请受理
证券之星 · 05-19
东诚药业：氟[18F]思睿肽注射液已获上市申请受理
股市必读：东诚药业（002675）5月15日披露最新机构调研信息
证券之星 · 05-18
股市必读：东诚药业（002675）5月15日披露最新机构调研信息
东诚药业：蓝纳成证监会备案正在审理中
证券之星 · 05-13
东诚药业：蓝纳成证监会备案正在审理中
东诚药业（002675）披露回购公司股份进展情况公告，5月6日股价上涨0.23%
证券之星 · 05-06
东诚药业（002675）披露回购公司股份进展情况公告，5月6日股价上涨0.23%
公司概况
公司名称：
烟台东诚药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2012-05-25
主营业务：
烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。
发行价格：
26.00
{"stockData":{"symbol":"002675","market":"SZ","secType":"STK","nameCN":"东诚药业","latestPrice":12.58,"timestamp":1784699058000,"preClose":12.61,"halted":0,"volume":9254300,"delay":0,"changeRate":-0.0024,"floatShares":743000000,"shares":825000000,"eps":0.2478,"marketStatus":"交易中","change":-0.03,"latestTime":"07-22 13:44:18","open":12.53,"high":12.75,"low":12.37,"amount":116000000,"amplitude":0.0301,"askPrice":12.59,"askSize":106,"bidPrice":12.58,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.2478,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1784703600000},"marketStatusCode":2,"adr":0,"adjPreClose":12.61,"symbolType":"stock","openAndCloseTimeList":[[1784683800000,1784691000000],[1784696400000,1784703600000]],"highLimit":13.87,"lowLimit":11.35,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":824595705,"isCdr":false,"pbRate":2.43,"roa":"--","peRate":50.766747,"roe":"0.77%","epsLYR":0.2372,"committee":-0.596656,"marketValue":10373000000,"turnoverRate":0.0124,"status":1,"floatMarketCap":9352000000},"requestUrl":"/m/hq/s/002675/wiki","defaultTab":"wiki","newsList":[{"id":"2649677478","title":"东诚药业：177Lu-LNC1011为前列腺癌治疗核素药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2649677478","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649677478?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:27","pubTimestamp":1783384023,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业07月06日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，看到贵司的1001，CDE审评排位116位，是不是快获批了？前列癌治疗药物1011，本次 递交招股书比上次递交招股书的进展快了很多，临床数据怎么样？本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700006867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648508544","title":"东诚药业（002675）披露回购公司股份进展情况公告，7月1日股价上涨1.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648508544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648508544?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:59","pubTimestamp":1782917949,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，东诚药业报收于12.78元，较前一交易日上涨1.83%，最新总市值为105.38亿元。该股当日开盘12.53元，最高12.83元，最低12.35元，成交额达1.28亿元，换手率为1.36%。近日，东诚药业发布《关于回购公司股份进展情况的公告》。公告指出，回购符合相关法规及公司既定方案，公司未在禁止回购期间进行操作，委托价格及时段均符合监管要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648015543","title":"东诚药业：18F-LNC1001思睿肽注射液目前正在审核中","url":"https://stock-news.laohu8.com/highlight/detail?id=2648015543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648015543?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:53","pubTimestamp":1782910396,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业07月01日在投资者关系平台上答复投资者关心的问题。投资者提问：1、18F-LNC-1001思睿肽注射液，有可能中国最早上市的前列腺癌核素诊断药物，CDE官网审评进度116位，请问目前是什么状态？东诚药业回复：您好，1、18F-LNC1001思睿肽注射液前期已提交上市申请，并于2026年1月9日获得CDE受理，目前正在审核中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100041224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647345215","title":"东诚药业（002675）披露为合营公司提供8000万元担保进展，6月30日股价下跌1.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647345215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647345215?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:53","pubTimestamp":1782813198,"startTime":"0","endTime":"0","summary":"截至2026年6月30日收盘，东诚药业报收于12.55元，较前一交易日下跌1.49%，最新总市值为103.49亿元。近日，东诚药业发布《关于为合营公司提供担保的进展公告》。齐康原股东EZ按其持有的50%股权向公司提供4,000万元反担保。公司已于2026年3月25日和4月15日通过董事会及股东会审议，同意2026年度为齐康原提供不超过38,000万元担保额度。截至公告日，公司实际对外担保余额为117,800万元，占2025年经审计净资产的27.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000033587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645019860","title":"股市必读：东诚药业（002675）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645019860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645019860?lang=zh_cn&edition=full","pubTime":"2026-06-22 05:37","pubTimestamp":1782077831,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，东诚药业报收于12.72元，上涨0.32%，换手率0.84%，成交量6.23万手，成交额7938.55万元。董秘最新回复投资者： 你好，贵公司子公司蓝纳成港股上市证监会备案审理用时已经260天，在备案历史时间来说已经算是很长的，请问目前备案遇到什么障碍了吗？投资者： 董秘您好，请问截至2026年6月11日收盘，公司最新的股东人数是多少？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203602","title":"东诚药业最新公告：子公司蓝纳成重新递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643203602?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:00","pubTimestamp":1781524842,"startTime":"0","endTime":"0","summary":"东诚药业(002675.SZ)公告称，公司所属子公司烟台蓝纳成生物技术股份有限公司于2026年6月12日向香港联交所重新递交H股发行上市申请，并刊发申请资料。该申请为草拟版本，可能适时更新。本次发行尚需取得证监会、香港证监会及香港联交所等监管机构的备案或批准，存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500030033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643279784","title":"东诚药业(002675.SZ)：吉林长春核药生产中心投入运营","url":"https://stock-news.laohu8.com/highlight/detail?id=2643279784","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643279784?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:58","pubTimestamp":1781513926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东诚药业(002675.SZ)发布公告，近日，公司收到全资子公司南京江原安迪科正电子研究发展有限公司(以下简称“安迪科”)的通知，通知其收到江苏省药品监督管理局下发的《放射性药品生产许可证》，新增吉林长春核药生产中心。此次审查的通过标志着安迪科的吉林长春核药生产中心已达到投产要求，安迪科将新增一个核药生产中心。核药生产中心投产后，将有利于安迪科开拓市场、提升销售收入，进一步完善全国核药网络化建设布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643245815","title":"蓝纳成冲刺港股：年亏1.5亿 东诚药业是大股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2643245815","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643245815?lang=zh_cn&edition=full","pubTime":"2026-06-14 12:55","pubTimestamp":1781412930,"startTime":"0","endTime":"0","summary":"烟台蓝纳成生物技术股份有限公司（简称：“蓝纳成”）日前更新招股书，准备在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260614/6391703847153512417752524.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260614/6391703847153512417752524.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34024/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4585","002675","VXUS","BK4588","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642945989","title":"东诚药业：氟[18F]思睿肽注射液不符合医保目录预申报条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2642945989","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642945989?lang=zh_cn&edition=full","pubTime":"2026-06-09 11:34","pubTimestamp":1780976042,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)06月08日在投资者关系平台上答复投资者关心的问题。投资者提问：按照最新医保政策，公司的氟[18F]思睿肽注射液是否符合预申报的条件，是否有望搭上2026年的医保申报快车。东诚药业回复：您好，根据最新医保政策，氟[18F]思睿肽注射液不符合医保目录预申报条件。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900015101.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640922604","title":"东诚药业：齐康原的回旋加速器项目尚未正式投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2640922604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640922604?lang=zh_cn&edition=full","pubTime":"2026-06-03 08:54","pubTimestamp":1780448050,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司投资的合资公司常州齐康原医疗科技有限公司，医用同位素AC 225正式投产并对外销售了吗？东诚药业回复：您好，齐康原的回旋加速器项目尚未正式投产，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300010055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640636922","title":"东诚药业：公司目前持有四川中硼联康医疗科技集团有限公司10.3949%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640636922","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640636922?lang=zh_cn&edition=full","pubTime":"2026-06-03 08:46","pubTimestamp":1780447572,"startTime":"0","endTime":"0","summary":"投资者提问：尊敬的懂秘： 在2025年12月份仍知悉贵公司参股南宁中硼联康医疗科技有限公司，但在今年5月份在爱企查中获悉四川中硼联康医疗科技集团有限公司的股东里已经没有贵公司的持股信息！东诚药业回复：您好，公司目前持有四川中硼联康医疗科技集团有限公司10.3949%的股份，请以国家企业信用信息公示系统为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300009878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","159891","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911953","title":"东诚药业（002675）披露为全资子公司提供3亿元担保公告，6月2日股价下跌0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911953","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640911953?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:46","pubTimestamp":1780393564,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，东诚药业报收于12.73元，较前一交易日下跌0.39%，最新总市值为104.97亿元。近日，东诚药业发布《关于为全资子公司提供担保的进展公告》。公告显示，烟台东诚药业集团股份有限公司与平安银行股份有限公司烟台分行签订《保证担保合同》，为全资子公司南京江原安迪科正电子研究发展有限公司向平安银行申请的30,000万元贷款提供连带责任担保。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640733993","title":"东诚药业：东诚安迪科与诺华开展核药供应链相关的业务合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2640733993","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640733993?lang=zh_cn&edition=full","pubTime":"2026-06-02 08:57","pubTimestamp":1780361837,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)06月01日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好。公司跟诺华的合作进展如何了？诺华的核药销售要借助公司的核药房及相关渠道吧，预计2026年此合作能给公司带来多少收益呢东诚药业回复：您好，东诚安迪科与诺华开展核药供应链相关的业务合作，包括核药清关，运输，药品检验服务等工作，未来将会开展深度合作。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200008640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638691071","title":"东诚药业（002675）披露2026年第一次临时股东会决议公告，5月28日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638691071","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638691071?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:37","pubTimestamp":1779979031,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，东诚药业报收于12.57元，较前一交易日下跌0.32%，最新总市值为103.65亿元。公司于近日发布《2026年第一次临时股东会决议公告》。公告显示，烟台东诚药业集团股份有限公司于2026年5月28日召开2026年第一次临时股东会，会议由董事会召集，董事长由守谊主持，采用现场与网络投票相结合方式表决。表决结果为同意股占出席会议股东所持有效表决权股份的97.6956%，反对占2.2719%，弃权占0.0325%。中小股东中同意占12.5104%，反对占86.2571%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638695923","title":"东诚药业：蓝纳成证监会备案正在审理中","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695923","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638695923?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:52","pubTimestamp":1779972769,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)05月28日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好。子公司蓝纳成港股上市推进速度太慢了吧，同时公司股价长期在低位徘徊回购速度也太慢了吧？东诚药业回复：您好，蓝纳成证监会备案正在审理中，同时蓝纳成香港 IPO 材料正在更新中，递交后公司将会及时披露；公司股份回购正常推进中，请您关注相关公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800041240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637410805","title":"东诚药业：云克药业的钇90核素已开展定制化生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2637410805","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637410805?lang=zh_cn&edition=full","pubTime":"2026-05-21 11:33","pubTimestamp":1779334392,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好。子公司云克药业的钇一90核素对外销售了吗？26年会带耒多少收益呢东诚药业回复：您好，云克药业的钇90核素已开展定制化生产，目前整体收入相对较小。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100018680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636838740","title":"东诚药业：氟[18F]思睿肽注射液已获上市申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2636838740","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636838740?lang=zh_cn&edition=full","pubTime":"2026-05-19 15:09","pubTimestamp":1779174555,"startTime":"0","endTime":"0","summary":"证券之星消息，东诚药业(002675)05月19日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司，新药氟“18F”思睿肽注射液目前审批到什么进度了，预计什么时间能够获批上市？这款产品如果获批上市在国内属于首家产品吗？东诚药业回复：您好，关于氟[18F]思睿肽注射液目前国内未有同类产品上市，公司已收到国家药品监督管理局核准签发的上市许可申请的《受理通知书》，预计具体获批时间尚未确定，后续如有相关进度将会及时进行公告。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900021683.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636015616","title":"股市必读：东诚药业（002675）5月15日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2636015616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636015616?lang=zh_cn&edition=full","pubTime":"2026-05-18 02:43","pubTimestamp":1779043389,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，东诚药业报收于12.55元，下跌1.34%，换手率1.16%，成交量8.6万手，成交额1.09亿元。米度营业成本上升较大，主要由于美国临床中心首年投入使用导致人员及折旧成本增加较多。蓝纳成将重新递交招股书，相关产品进展、团队构成、专家引进及经营情况将在招股书中详细披露，请关注后续公告。答：2025年财务费用较高，主要系米度及蓝纳成对外融资所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800001137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002675","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635778754","title":"东诚药业：蓝纳成证监会备案正在审理中","url":"https://stock-news.laohu8.com/highlight/detail?id=2635778754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635778754?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:52","pubTimestamp":1778676732,"startTime":"0","endTime":"0","summary":"作为公司在二级市场上的长期持股小股东，第一：请问一下子公司蓝纳成港股何时上市？东诚药业回复：您好，蓝纳成证监会备案正在审理中，同时蓝纳成香港 IPO 材料正在更新中，递交后公司将会及时披露，请您关注相关公告；锝[99mTc]替曲膦注射液是诊断用核素药物，主要用于SPECT心肌灌注显像剂，目前暂无延伸其他适应症；18F-APN-1607 产品正在按照 CDE 要求补充相关临床实验，公司正在积极推进研发进度，争取早日上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300042456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633134547","title":"东诚药业（002675）披露回购公司股份进展情况公告，5月6日股价上涨0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633134547","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633134547?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:38","pubTimestamp":1778078298,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，东诚药业报收于13.02元，较前一交易日上涨0.23%，最新总市值为107.36亿元。该股当日开盘12.99元，最高13.24元，最低12.91元，成交额达1.43亿元，换手率为1.47%。近日，烟台东诚药业集团股份有限公司披露《关于回购公司股份进展情况的公告》。公告显示，公司于2025年12月31日召开董事会，审议通过以集中竞价方式回购股份的方案，拟使用自有及自筹资金回购股份，用于股权激励和/或员工持股计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600040008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002675"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784699061218,"stockEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0086},{"period":"3month","weight":-0.09},{"period":"6month","weight":-0.1341},{"period":"1year","weight":-0.1805},{"period":"ytd","weight":-0.0767}],"compareEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":-0.0553},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0626},{"period":"1year","weight":0.0856},{"period":"ytd","weight":-0.0263}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"烟台东诚药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"39547人(较上一季度增加45.95%)","perCapita":"18797股","listingDate":"2012-05-25","address":"山东省烟台市福山区经济技术开发区长白山路7号","registeredCapital":"82459万元","survey":" 烟台东诚药业集团股份有限公司的主营业务是放射性核素药物、抗凝血肝素类原料药及其下游制剂的生产销售。公司的主要产品是肝素钠原料药、硫酸软骨素、制剂产品、核素药物。","listedPrice":26},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东诚药业,002675,东诚药业股票,东诚药业股票老虎,东诚药业股票老虎国际,东诚药业行情,东诚药业股票行情,东诚药业股价,东诚药业股市,东诚药业股票价格,东诚药业股票交易,东诚药业股票购买,东诚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东诚药业(002675)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东诚药业(002675)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}